Aurinia Pharmaceuticals Inc (AUPH)

Currency in USD
15.210
-0.010(-0.07%)
Closed·
15.250+0.040(+0.26%)
·
AUPH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
14.95015.470
52 wk Range
6.55016.540
Key Statistics
Prev. Close
15.22
Open
15.17
Day's Range
14.95-15.47
52 wk Range
6.55-16.54
Volume
897.41K
Average Volume (3m)
1.43M
1-Year Change
89.8876%
Book Value / Share
2.78
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AUPH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
16.667
Upside
+9.58%
Members' Sentiments
Bearish
Bullish
ProTips
Holds more cash than debt on its balance sheet
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Aurinia Pharmaceuticals Inc Company Profile

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Employees
130

Aurinia Pharmaceuticals Inc Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of $0.16 beat $0.14 forecast; revenue of $70M exceeded $64.27M estimate, driving 15.91% stock surge
  • Net product sales of Lupkynis reached $66.6M; full-year 2025 revenue guidance raised to $260-$270M
  • Cash flow from operations improved to $45.5M; cash and investments totaled $315.1M as of June 30, 2025
  • Company plans to initiate clinical studies in at least two autoimmune diseases in H2 2025
  • CEO emphasized focus on operational efficiency and exploration of new therapeutic areas
Last Updated: 21/08/2025, 14:40
Read Full Transcript

Compare AUPH to Peers and Sector

Metrics to compare
AUPH
Peers
Sector
Relationship
P/E Ratio
25.8x20.1x−0.6x
PEG Ratio
0.060.110.00
Price/Book
5.5x6.5x2.6x
Price / LTM Sales
7.5x5.4x3.3x
Upside (Analyst Target)
8.4%37.4%45.0%
Fair Value Upside
Unlock16.7%6.5%Unlock

Analyst Ratings

4 Buy
3 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 16.667
(+9.58% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Leerink Partners
Hold16.00+5.19%-DowngradeDec 03, 2025
Jefferies
Buy21.00+38.07%10.00UpgradeNov 07, 2025
RBC Capital
Hold15.00-1.38%9.00DowngradeNov 05, 2025
Jefferies
Hold10.00-34.25%-MaintainSep 30, 2025
RBC Capital
Buy9.00-40.83%8.00MaintainAug 01, 2025

Earnings

Latest Release
Nov 04, 2025
EPS / Forecast
0.23 / 0.16
Revenue / Forecast
73.47M / 67.70M
EPS Revisions
Last 90 days

AUPH Income Statement

People Also Watch

695.51
SNDK
+4.55%
42.59
EXEL
-0.51%
276.52
CIEN
+2.99%
25.220
CPRX
+0.88%
111.31
CRDO
-7.21%

FAQ

What Is the Aurinia Pharma (AUPH) Premarket Price Today?

The Aurinia Pharma (AUPH) premarket price is 15.290. Premarket price change units: 0.070. Premarket percentage change: 0.460%. Premarket volume: 470.000. Current date: 04 Feb 2026. Previous close: 15.220

What Stock Exchange Does Aurinia Pharma Trade On?

Aurinia Pharma is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Aurinia Pharma?

The stock symbol for Aurinia Pharma is "AUPH."

What Is the Aurinia Pharma (AUPH) Afterhours Price Today? (Afterhours variable test: 15.250) Current Date: 04 Feb 2026

After hours price: 15.250. After hours price change (units): 0.040. Price change percentage: 0.260%

What Is the Aurinia Pharma Market Cap?

As of today, Aurinia Pharma market cap is 2.01B.

What Is Aurinia Pharma's Earnings Per Share (TTM)?

The Aurinia Pharma EPS (TTM) is 0.55.

When Is the Next Aurinia Pharma Earnings Date?

Aurinia Pharma will release its next earnings report on 03 Mar 2026.

From a Technical Analysis Perspective, Is AUPH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Aurinia Pharma Stock Split?

Aurinia Pharma has split 1 times.

How Many Employees Does Aurinia Pharma Have?

Aurinia Pharma has 130 employees.

What is the current trading status of Aurinia Pharma (AUPH)?

As of 04 Feb 2026, Aurinia Pharma (AUPH) is trading at a price of 15.210, with a previous close of 15.220. The stock has fluctuated within a day range of 14.950 to 15.470, while its 52-week range spans from 6.550 to 16.540.

What Is Aurinia Pharma (AUPH) Price Target According to Analysts?

The average 12-month price target for Aurinia Pharma is USD16.667, with a high estimate of USD21 and a low estimate of USD13. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +9.58% Upside potential.

What Is the AUPH Premarket Price?

AUPH's last pre-market stock price is 15.290. The pre-market share volume is 470.000, and the stock has decreased by 0.070, or 0.460%.

What Is the AUPH After Hours Price?

AUPH's last after hours stock price is 15.250, the stock has decreased by 0.040, or 0.260%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.